This Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and safety of MEDI5752 as monotherapy (MONO) and in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).~This study has a modular design with independent substudies. In Substudy 1, MEDI5752 will be evaluated as monotherapy and in combination with bevacizumab or lenvatinib in approximately 120 evaluable participants with advanced HCC.
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.